(Q39269039)

English

Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 September 2017

Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study (English)

1 reference

Europe PubMed Central

10 September 2017

0 references

quality of life

1 reference

based on heuristic

inferred from title

irritable bowel syndrome

1 reference

based on heuristic

inferred from title

Bifidobacterium bifidum

object named as

Bifidobacterium bifidum

1 reference

based on heuristic

inferred from title

object named as

D Mora

2

0 references

Simone Guglielmetti

object named as

S Guglielmetti

1

0 references

author name string

M Gschwender

3

1 reference

Europe PubMed Central

10 September 2017

K Popp

4

1 reference

Europe PubMed Central

10 September 2017

language of work or name

0 references

publication date

21 March 2011

1 reference

Europe PubMed Central

10 September 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

10 September 2017

33

1 reference

Europe PubMed Central

10 September 2017

1123-1132

1 reference

Europe PubMed Central

10 September 2017

10

1 reference

Europe PubMed Central

10 September 2017

Functional bowel disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome--a longitudinal study in IBS and control subjects.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Probiotic agents and infectious diseases: a modern perspective on a traditional therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Implication of an outer surface lipoprotein in adhesion of Bifidobacterium bifidum to Caco-2 cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Study of the adhesion of Bifidobacterium bifidum MIMBb75 to human intestinal cell lines.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Intestinal microecology and quality of life in irritable bowel syndrome patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Probiotics in irritable bowel syndrome: an immunomodulatory strategy?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04633.X

21 January 2018

Identifiers

10.1111/J.1365-2036.2011.04633.X

1 reference

Europe PubMed Central

10 September 2017

1 reference

Europe PubMed Central

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39269039&oldid=1817636659"